drugset / Trial / NCT05275205
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Timeline
- Start
- 2022-03-02
- Primary completion
- 2023-02-15
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 0.05 ml | — |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | — |
| Subject | foselutoclax | Small molecule | 0.05 ml | Intravitreal |